Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MYGN

MYGN - Myriad Genetics Inc Stock Price, Fair Value and News

$5.72-0.20 (-3.38%)
Market Closed

52/100

MYGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

52/100

MYGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.08

Target 3M

$5.92

Target 6M

$5.98

MYGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MYGN Price Action

Last 7 days

-2.1%

Last 30 days

-9.3%

Last 90 days

-28.1%

Trailing 12 Months

-54.2%

MYGN RSI Chart

MYGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MYGN Valuation

Market Cap

533.2M

Price/Earnings (Trailing)

-1.33

Price/Sales (Trailing)

0.65

EV/EBITDA

-1.05

Price/Free Cashflow

-242.36

MYGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.08

Target 3M

$5.92

Target 6M

$5.98

MYGN Fundamentals

MYGN Revenue

Revenue (TTM)

825.3M

Rev. Growth (Yr)

-3.56%

Rev. Growth (Qtr)

-3.47%

MYGN Earnings

Earnings (TTM)

-400.5M

Earnings Growth (Yr)

-23.98%

Earnings Growth (Qtr)

91.71%

MYGN Profitability

Operating Margin

82.27%

EBT Margin

-51.54%

Return on Equity

-107.43%

Return on Assets

-55.01%

Free Cashflow Yield

-0.41%

MYGN Investor Care

Shares Dilution (1Y)

2.39%

Diluted EPS (TTM)

-4.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025831.3M832.9M825.3M0
2024774.2M802.2M823.6M837.6M
2023694.7M698.9M734.4M753.2M
2022682.4M672.3M661.4M678.4M
2021566.1M662.3M684.4M690.6M
2020760.8M638.6M597.5M557.0M
2019829.6M851.1M835.1M813.4M
2018749.4M743.7M767.2M796.1M
2017743.5M769.9M769.8M761.0M
2016756.6M740.5M735.9M739.3M
2015721.9M722.5M737.2M746.1M
2014763.6M778.2M744.5M724.9M
2013572.0M613.2M682.2M737.1M
2012470.5M496.0M519.0M545.3M
2011388.6M402.1M420.7M443.0M
2010000377.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Myriad Genetics Inc

MYGN
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
 CEO
 WEBSITEhttps://myriad.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES2600

Myriad Genetics Inc Frequently Asked Questions

MYGN is the stock ticker symbol of Myriad Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Myriad Genetics Inc is 533.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MYGN's fair value in chart for subscribers.

The fair value guage provides a quick view whether MYGN is over valued or under valued. Whether Myriad Genetics Inc is cheap or expensive depends on the assumptions which impact Myriad Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MYGN.

As of Wed Jan 28 2026, MYGN's PE ratio (Price to Earnings) is -1.33 and Price to Sales (PS) ratio is 0.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MYGN PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Myriad Genetics Inc has provided -0.175 (multiply by 100 for percentage) rate of return.